Sakdejayont Siwat, Chobpenthai Thanapon, Suksirivecharuk Ploy, Ninatkiattikul I-Fan, Poosiripinyo Thanate
Princess Srisavangavadhana Faculty of Medicine, Chulabhorn Royal Academy, Bangkok, Thailand.
Department of Orthopaedics, Khon Kaen Hospital, Khon Kaen, Thailand.
Orthop Res Rev. 2025 May 7;17:175-188. doi: 10.2147/ORR.S521832. eCollection 2025.
Bone tumors present complex challenges in orthopaedic oncology, requiring precise management strategies to restore skeletal integrity and function with minimal morbidity. Traditional autologous bone grafting has been the gold standard due to its osteogenic, osteoconductive, and osteoinductive properties. However, limitations such as donor site morbidity and graft availability have prompted the development of alternative approaches.This review evaluates contemporary approaches in bone tumor management, focusing on advancements in bone grafting techniques, bone graft substitutes (eg, ceramics, polymers, bioactive materials), and growth factor-based therapies. The efficacy and safety of these substitutes are compared with autografts, examining their potential benefits and drawbacks.Recent innovations in bone graft substitutes show promise in overcoming autograft limitations. Ceramic, polymer, and bioactive materials offer diverse properties that may enhance bone regeneration. Growth factor-based therapies, including bone morphogenetic proteins (BMPs) and vascular endothelial growth factor (VEGF), have revolutionized bone healing by stimulating osteogenesis and angiogenesis.
骨肿瘤在骨肿瘤学领域带来了复杂的挑战，需要精确的管理策略，以在最小化发病率的情况下恢复骨骼的完整性和功能。传统的自体骨移植因其成骨、骨传导和骨诱导特性一直是金标准。然而，诸如供区发病率和移植物可用性等限制促使了替代方法的发展。本综述评估了骨肿瘤管理的当代方法，重点关注骨移植技术、骨移植替代物（如陶瓷、聚合物、生物活性材料）和基于生长因子的疗法的进展。将这些替代物的疗效和安全性与自体移植进行比较，审视它们的潜在益处和缺点。骨移植替代物的最新创新在克服自体移植限制方面显示出前景。陶瓷、聚合物和生物活性材料具有多样的特性，可能会增强骨再生。基于生长因子的疗法，包括骨形态发生蛋白（BMP）和血管内皮生长因子（VEGF），通过刺激成骨和血管生成彻底改变了骨愈合。
